Yes, agree - the chance of failure has been greatly reduced with...

Yes, agree - the chance of failure has been greatly reduced with the first efficacy hurdle completed. So much so that I believe a level of success is inevitable; The drug works a little or maybe a lot, we just know it works. So failure is not really an option which is why I hold no fully paid shares at all and in doing so have about 30% more than I could otherwise afford / risk via the oppies.

I think dxb will do at least one deal before this time next year to build cash prior to the readout. But I suspect theyll leave usa? as the big kahuna deal after results are released which will command the type of upfront you read about in science news articles.